Introduction
How can emerging pharmaceutical research be considered alongside biodiversity conservation and public-health safeguards? This narrative review and policy proposal examines that question in Goa, India. It advocates baseline fungal surveys before any development, followed only where evidence and explicit approvals support it by conservation measures and regulated clinical research. Local occurrence of psilocybin-producing species remains unverified in the manuscript; the proposed initiatives are not established programs or approved treatments.
Abstract
The manuscript examines the environmental, economic, and regulatory rationale for studying psilocybin-containing fungi in Goa. It distinguishes documented species records from Kerala from the unverified possibility of their presence in Goa, making systematic taxonomic investigation the starting point rather than assuming a local resource exists.
Two initiatives are proposed: survey-first myco-reserves for habitat protection and species verification, and a formally licensed therapy and research unit under the Institute of Psychiatry and Human Behaviour. The review discusses psychiatric research, commercial uncertainty, access and benefit sharing, and conflicting judicial interpretations concerning mushroom biomass in India.
This is a narrative review and policy proposal, not an original clinical trial or field survey. The document identifies Cureus as its target journal; acceptance, publication, and peer-review status have not been confirmed. It is provided for research discussion, not as medical or legal advice or an endorsement of unsupervised use.
Paper Info
Status
Authors
Shruti Malik, MBBS, MHSA, CPhT
Domain
PharmaLanding